期刊文献+
共找到11篇文章
< 1 >
每页显示 20 50 100
Serum vascular endothelial growth factor is a potential biomarker of metastatic recurrence after curative resection of hepatocellular carcinoma 被引量:20
1
作者 Qi Niu Zhao You Tang +2 位作者 Zeng Chen Ma Lun Xiu Qin Lian Hai Zhang 《World Journal of Gastroenterology》 SCIE CAS CSCD 2000年第4期565-568,共4页
Hepatocellular carcinoma (HCC) is one of the most common malignancies in China. To date, surgery is still the best solution to it. However, metastatic recurrences after curative hepatic resections are very common. Tan... Hepatocellular carcinoma (HCC) is one of the most common malignancies in China. To date, surgery is still the best solution to it. However, metastatic recurrences after curative hepatic resections are very common. Tang et al have reported that recurrence rate within 5 years of curative hepatic resection is 61.5% [1]. As curative hepatic resection has a high tendency for metastatic recurrence, therapeutic interventions such as transarterial embolization and antiangiogenesis have been tried to further improve prognosis of HCC patients. Therefore, establishing a dependable, sensitive, easy, and economical method to predict metastatic recurrence following curative hepatic resection is of clinical urgency. 展开更多
关键词 ENDOTHELIUM vascular ENDOTHELIAL growth factor carcinoma hepatocellular enzyme-linked immunosorbent assay LIVER neoplasms LIVER cirrhosis immunohistochemistry
下载PDF
Reduction of tumorigenicity of SMMC-7721 hepatoma cells by vascular endothelial growth factor antisense gene therapy 被引量:33
2
作者 Yu Cheng Tang Yu Li Guan Xiang Qian Department of Biochemistry, Shanghai Second Medical University, Shanghai 200025, China 《World Journal of Gastroenterology》 SCIE CAS CSCD 2001年第1期22-27,共6页
AIM: To test the hypothesis to block VEGF expression of SMMC-7721 hepatoma cells may inhibit tumor growth using the rat hepatoma model. METHODS: Amplify the 200 VEGF cDNA fragment and insert it into human U6 gene cass... AIM: To test the hypothesis to block VEGF expression of SMMC-7721 hepatoma cells may inhibit tumor growth using the rat hepatoma model. METHODS: Amplify the 200 VEGF cDNA fragment and insert it into human U6 gene cassette in the reverse orientation transcribing small antisense RNA which could specifically interact with VEGF165, and VEGF121 mRNA. Construct the retroviral vector containing this antisense VEGF U6 cassette and package the replication-deficient recombinant retrovirus. SMMC-7721 cells were transduced with these virus and positive clones were selected with G418. PCR and Southern blot analysis were performed to determine if U6 cassette integrated into the genomic DNA of positive clone. Transfected tumor cells were evaluated for RNA expression by ribonuclease protection assays. The VEGF protein in the supernatant of parental tumor cells and genetically modified tumor cells was determined with ELISA. In vitro and in vivo growth properties of antisense VEGF cell clone in nude mice were analyzed. RESULTS: Restriction enzyme digestion and PCR sequencing verified that the antisense VEGF RNA retroviral vector was successfully constructed.After G418 selection, resistant SMMC-7721 cell clone was picked up. PCR and Southern blot analysis suggested that U6 cassette was integrated into the cell genomic DNA. Stable SMMC-7721 cell clone transduced with U6 antisense RNA cassette could express 200 bp small antisense VEGF RNA and secrete reduced levels of VEGF in culture condition. Production of VEGF by antisense transgene-expressing cells was 65+/-10 ng/L per 10(6) cells, 42045 ng/L per 10(6) cells in sense group and 485+/-30 ng/L per 10(6) cells in the negative control group, (P【 0.05). The antisense-VEGF cell clone appeared phenotypically indistinguishable from SMMC-7721 cells and SMMC-7721 cells transfected sense VEGF. The growth rate of the antisense-VEGF cell clone was the same as the control cells. When S.C. was implanted into nude mice, growth of antisense-VEGF cell lines was greatly inhibited compared with control cells. CONCLUSION: Expression of antisense VEGF RNA in SMMC-7721 cells could decrease the tumorigenicity, and antisense-VEGF gene therapy may be an adjuvant treatment for hepatoma. 展开更多
关键词 Gene Therapy Animals Carcinoma Hepatocellular Cell Division DNA Polymerase III Endothelial growth factors Endothelium Vascular enzyme-linked immunosorbent assay Gene Expression Humans Liver neoplasms LYMPHOKINES MICE Mice Nude Neovascularization Pathologic Promoter Regions (Genetics) RNA Antisense Research Support Non-U.S. Gov't Transduction Genetic Tumor Cells Cultured Vascular Endothelial growth factor A Vascular Endothelial growth factors
下载PDF
Serum Vascular Endothelial Growth Factor-C and Vascular Endothelial Growth Factor Level in Patients with Colorectal Carcinoma and Clinical Significance 被引量:16
3
作者 许天文 陈道达 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2006年第3期329-331,355,共4页
Circulating vascular endothelial growth factor-C (VEGF-C) and vascular endothelial growth factor (VEGF) levels in patients with colorectal carcinoma were determined in order to assess their clinical significance a... Circulating vascular endothelial growth factor-C (VEGF-C) and vascular endothelial growth factor (VEGF) levels in patients with colorectal carcinoma were determined in order to assess their clinical significance as a diagnostic tool for monitoring lymph node metastasis. In 66 patients with colorectal carcinoma and 30 healthy controls, circulating VEGF-C and VEGF levels were assessed by using enzyme-linked immunosorbent assay (ELISA). Serum VEGF-C and VEGF levels were higher in patients with colorectal carcinoma than in healthy controls. Patients with lymph node metastasis had higher serum VEGF-C and VEGF levels than those without lymph node metastasis. The levels of VEGF-C and VEGF were higher in the invasion group than in the non-invasion group. Serum VEGF-C levels reached a sensitivity of 81% and a specificity of 76 % with a cutoff value of 1438.0 pg/mL, whereas VEGF levels reached 72 % sensitivity and 74 % specificity at 240.2 pg/ mL. If 66 patients were divided into 4 groups according to the combined determination of VEGF-C and VEGF levels, the positive predictive value was 85.3 %, the negative predictive value was 94.6 %, and accuracy was 93.7 %. It was suggested that circulating VEGF-C levels might provide additional information for distinguishing the absence from presence of lymph node metastasis in patients with colorectal carcinoma. The combined determination of VEGF-C and VEGF levels could be used as an important index for preoperatively clinical stage of colorectal carcinoma. 展开更多
关键词 colorectal carcinoma vascular endothelial growth factor C vascular endothelial growth factor lymph node metastasis enzyme-linked immunosorbent assay
下载PDF
Establishment of a Sandwich ELISA Method for Detection of Vascular Endothelial Growth Factor in Serum Samples of Hepatocellular Carcinoma Patients 被引量:4
4
作者 BING SHAN CHEN GAO +10 位作者 JIAN-MING CHEN XIN-Yu BI BAO-YUN ZHANG YAN GUO CHEN-FANG DONG RUN AN QI SHI JING-QUN HU PING ZHAO JUN HAN XIAO-PING DONG 《Biomedical and Environmental Sciences》 SCIE CAS CSCD 2008年第1期69-74,共6页
Objective To establish a sandwich ELISA method for detecting vascular endothelial growth factor (VEGF) in sera of population and the patients with hepatocellular carcinoma (HCC). Methods Full length and two trunca... Objective To establish a sandwich ELISA method for detecting vascular endothelial growth factor (VEGF) in sera of population and the patients with hepatocellular carcinoma (HCC). Methods Full length and two truncated human VEGF cDNA sequences were amplified from a commercial plasmid pBLAST49-hVEGF by PCR and inserted into the prokaryotic-expression plasmid pET-32a or pGEX-2T. Various VEGF proteins were expressed and purified from E. coli in His-Trx or GST fusion forms. The specific VEGF antibodies were elicited in experimental rabbits and mice by immunization of the full length VEGF fusion protein His-Trx-VEGF1-165. After purification of antibodies with chromatograph of Protein G, a sandwich ELISA technique was established. Serum VEGF levels were evaluated in 229 adults and 291 HCC patients. Results SDS-PAGE displayed that the molecular weights of the expressed full length (His-Trx-VEGF1-165), N-terminal (His-Trx-VEGF1-100) and C-terminal (GST-VEGF100-165) human VEGF fusion proteins were about 38KD, 31KD, and 33KD, respectively. Western blots confirmed that the prepared antisera were able to recognize both prokaryoticly and eukaryoticly expressed recombinant VEGF proteins. Assays of serially diluted His-Trx-VEGF1-100 by the established sandwich ELISA method showed that the linear range of the standard curve was 0.625-320 ng/mL, with the squared correlation coefficient R^2=0.991. Screening of a serum panel containing 291 serum samples of HCC patients and 229 health adults revealed that the average VEGF level in HCC patients was higher than that in healthy controls, with a statically significant difference. Conclusion The established sandwich ELISA reflects the level of serum VEGF and provide scientific basis for screening metastasis and recurrence of HCC using serum VEGF as an index. 展开更多
关键词 Hepatocellular carcinoma Vascular endothelial growth factor enzyme-linked immunosorbent assay
下载PDF
Diagnostic Values of Vascular Endothelial Growth Factor and Epidermal Growth Factor Receptor for Benign and Malignant Hydrothorax 被引量:19
5
作者 Yan Gu Min Zhang +8 位作者 Guo-Hua Li Jun-Zhen Gao Liping Guo Xiao-Juan Qiao Li-Hong Wang Lan He Mei-Ling Wang Li Yan Xiu-Hua Fu 《Chinese Medical Journal》 SCIE CAS CSCD 2015年第3期305-309,共5页
Background: Hydrothorax, as one of the common complications of malignant tumors, still cannot be sensitively detected in clinical practice, thus requiring a sensitive, specific method for diagnosis. The aim of this s... Background: Hydrothorax, as one of the common complications of malignant tumors, still cannot be sensitively detected in clinical practice, thus requiring a sensitive, specific method for diagnosis. The aim of this study was to analyze the correlation between levels of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) in patients with benign and malignant hydrothorax. Methods: The contents of VEGF in the pleural effusion and serum of the patients with malignant pleural effusion (n = 35) and benign pleural effusion (n = 30) were detected by double antibody sandwich enzyme linked immunosorbent assay. The gene copy number level of EGFR in pleural effusion was detected by fluorescence in situ hybridization (FISH). The points with the highest sensitivity and specificity were selected as the critical values to calculate the diagnostic value of the VEGF in pleural effusion and serum, and EGFR gene copy number in pleural effusion. Results: The contents of VEGF in pleural effusion and serum of patients with malignant hydrothorax were (384.91 ± 120.18), and (129.62 ±46.35) ng/L, respectively, which were significantly higher than those of the patients with benign hydrothorax (207.97 ± 64.04), (63.49 ± 24.58) ng/L (P 〈 0.01 ). The sensitivity and specificity of detecting VEGF in pleural effusion were 80.0% and 96.7% (the boundary value was 297.06 ng/L), respectively for diagnosing benign and malignant hydrothorax. The sensitivity and specificity of serum were 74.3% and 96.7%, respectively (the boundary value was 99.21 ng/L) for diagnosing benign and malignant hydrothorax. The diagnostic efficiencies of EGFR and VEGF in hydrothorax were similar. There was a significant correlation between EGFR and VEGF in hydrothorax (P 〈 0.01 ). Conclusions: VEGF and EGFR play important roles in the formation of pleural effusion. VEGF differed significantly in benign and malignant pleural effusions, which contributed to differential diagnosis results of benign and malignant pleural effusions. It is feasible to detect the gene copy number of the pleural effusion cell mass EGFR by FISH technique. Joint detection can improve the diagnostic sensitivity. 展开更多
关键词 enzyme-linked hnmunosorbent assay epidermal growth factor Receptor Fluorescence In Situ Hybridization HYDROTHORAX Vascular Endothelial growth factor
原文传递
乳腺癌患者血液HER-2浓度与组织HER-2表达水平的一致性研究 被引量:5
6
作者 陈建魁 曾利军 +9 位作者 左向华 陈祎霏 于农 宋世平 尹秀云 黄媛 金欣 王淼 张伟 田曙光 《国际检验医学杂志》 CAS 2013年第2期145-146,共2页
目的探讨复发转移乳腺癌患者血清HER-2浓度与组织HER-2表达水平的一致性。方法应用ELISA法测定血清HER-2浓度;应用免疫组化(IHC)法检测乳腺癌组织HER-2表达水平;对检测结果进行统计分析。结果组织HER-2阳性的复发转移乳腺癌患者中有62... 目的探讨复发转移乳腺癌患者血清HER-2浓度与组织HER-2表达水平的一致性。方法应用ELISA法测定血清HER-2浓度;应用免疫组化(IHC)法检测乳腺癌组织HER-2表达水平;对检测结果进行统计分析。结果组织HER-2阳性的复发转移乳腺癌患者中有62例血清HER-2阳性,阳性符合率为74.7%,组织HER-2阴性的患者有96例血清HER-2为阴性,阴性符合率为82.1%。血清HER-2水平与组织HER-2表达状态呈正相关(kappa=0.653,P<0.01)。结论复发转移乳腺癌患者血清HER-2浓度与组织HER-2表达水平无显著差别,两种检测方法具有较好的一致性,血清HER-2浓度可作为临床个体化治疗的参考依据。 展开更多
关键词 乳腺肿瘤 受体 表皮生长因子 酶联免疫吸附测定 免疫组织化学
下载PDF
表皮生长因子ELISA检测方法的建立及其在肿瘤临床的初步应用 被引量:1
7
作者 吴学诗 夏勇 张美英 《国外医学(临床生物化学与检验学分册)》 CAS 2005年第12期869-871,共3页
目的建立表皮生长因子(EGF)酶联免疫检测方法,探讨其在临床常见肿瘤患者血清中含量的变化规律。方法采用EGF单克隆抗体包被酶标板、兔抗EGF多抗为二抗,以辣根过氧化物酶(HRP)标记的羊抗兔IgG作为酶标抗体,建立夹心法ELISA,检测临床常见... 目的建立表皮生长因子(EGF)酶联免疫检测方法,探讨其在临床常见肿瘤患者血清中含量的变化规律。方法采用EGF单克隆抗体包被酶标板、兔抗EGF多抗为二抗,以辣根过氧化物酶(HRP)标记的羊抗兔IgG作为酶标抗体,建立夹心法ELISA,检测临床常见肿瘤患者及健康体检人群的血清EGF含量。结果建立的EGF酶联免疫吸附法最小检测限为15.6ng/L,批内精密度8.7%,批间精密度11.6%,平均回收率94.7%,符合临床检测要求。血清EGF含量在31名正常人为(1.305±0.382)ng/ml;24例乳腺癌患者术前为(0.729±0.347)ng/ml,术后为(0.711±0.332)ng/ml;17例结直肠癌患者术前为(0.678±0.311)ng/ml,术后为(0.658±0.298)ng/ml;19例胃癌患者术前为(0.598±0.224)ng/ml,术后为(0.614±0.257)ng/ml。各肿瘤组患者血清EGF水平较健康对照组明显降低(P<0.01)。结论建立了适用于临床检测EGF的ELISA法,肿瘤患者血清中EGF含量较健康对照组明显下降,为进一步探讨肿瘤的发病机制提供了有效手段。 展开更多
关键词 表皮生长因子 酶联免疫吸附测定 肿瘤
下载PDF
转化生长因子β1含量与喉癌侵袭转移
8
作者 辛丁 孙立群 +2 位作者 李石伟 滕博 崔树勋 《中国耳鼻咽喉头颈外科》 北大核心 2005年第8期482-482,共1页
关键词 喉肿瘤(Laryngeal neoplasms) 酶联免疫吸附测定(enzyme-linked immunosorbent assay) 转化生长因子β(Transforming growth factor beta) 转化生长因子Β1
下载PDF
夹心酶联免疫吸附试验检测人表皮生长因子的方法建立及其应用研究
9
作者 夏勇 吴学诗 张美英 《实用医学杂志》 CAS 2005年第14期1588-1590,共3页
目的:建立临床适用的表皮生长因子(epidermalgrowthfactor,EGF)酶联免疫检测方法,探讨EGF在临床常见肿瘤患者血清中的含量变化规律。方法:采用EGF单抗包被酶标板,兔抗EGF多抗为二抗,以辣根过氧化物酶标记的羊抗兔IgG作为酶标抗体建立夹... 目的:建立临床适用的表皮生长因子(epidermalgrowthfactor,EGF)酶联免疫检测方法,探讨EGF在临床常见肿瘤患者血清中的含量变化规律。方法:采用EGF单抗包被酶标板,兔抗EGF多抗为二抗,以辣根过氧化物酶标记的羊抗兔IgG作为酶标抗体建立夹心法ELISA检测临床常见肿瘤患者及健康体检人群的血清EGF含量。结果:建立的EGF酶联免疫吸附法最小检测限达15.6ng/L,批内精密度为8.7%,批间精密度为11.6%,平均回收率为94.7%,符合临床检测要求。血清EGF含量在31名正常人为(1.305±0.382)ng/mL,24名乳腺癌病人术前值为(0.729±0.347)ng/mL,术后为(0.711±0.332)ng/mL,17名结直肠癌病人术前为(0.678±0.311)ng/mL,术后为(0.658±0.298)ng/mL,19名胃癌病人术前为(0.598±0.224)ng/mL,术后为(0.614±0.257)ng/mL。各肿瘤组患者血清EGF水平较健康对照组明显降低(P<0.01)。结论:建立了适用于临床检测的EGF酶联免疫检测方法,肿瘤患者血清中EGF含量较健康对照组明显下降,该检测方法的建立为进一步探讨肿瘤的发病机制提供了有效的手段。 展开更多
关键词 夹心酶联免疫吸附试验 人表皮生长因子 方法建立 酶联免疫检测方法 血清EGF ELISA检测 酶联免疫吸附法 健康对照组 factor 含量变化规律 肿瘤患者 辣根过氧化物 病人术前 临床常见 临床检测 批间精密度 平均回收率 体检人群
下载PDF
FK506 effects on proliferation and secretion of Schwann cells
10
作者 Hua jun Jiang Wei Qu +2 位作者 Feng Han Wei guo Zhang De cheng Lu 《Neural Regeneration Research》 SCIE CAS CSCD 2011年第1期29-33,共5页
The immunosuppressive agent FK506 contributes to neural regeneration via growth cone and Schwann cell processes. However, it is difficult to rapidly harvest a large number of Schwann cells, and Schwann cell senescence... The immunosuppressive agent FK506 contributes to neural regeneration via growth cone and Schwann cell processes. However, it is difficult to rapidly harvest a large number of Schwann cells, and Schwann cell senescence is obvious following culture, proliferation, and amplification. The present study investigated the effects of various concentrations of FK506 on proliferation and secretion of cultured Schwann cells. In addition, the suitability of FK506 application as tissue engineered artificial nerves was considered. Bilateral sciatic nerves of 3-5-day old, Sprague Dawley rats were obtained, and primary cultured Schwann cells were identified by S-100 protein staining. Following subculture, Schwann cells purity was 〉 90%. After 3-5 days in culture, Schwann cell proliferation was visible in each group. Results verified that FK506 promoted proliferation of cultured Schwann cells and secretion of nerve growth factor. This effect was significant at a low concentration (1 × 10.8 mol/L). 展开更多
关键词 Schwann cells nerve growth factor MTT enzyme-linked immunosorbent assay FK506
下载PDF
Relationship between serum HER2 extracellular domain levels, tissue HER2 expression, and clinico-pathological parameters in early stage breast cancer 被引量:3
11
作者 MA Li YANG Hong-ying HAN Xiao-hong LI Jia WANG Fang ZHANG Chun-ling YAO Jia-rui SHI Yuan-kai 《Chinese Medical Journal》 SCIE CAS CSCD 2012年第22期4104-4110,共7页
Background Measurement of human epidermal growth factor receptor 2 (HER2) protein in the serum of metastatic breast cancer patients has previously been reported, but there are no consistent data to support the clini... Background Measurement of human epidermal growth factor receptor 2 (HER2) protein in the serum of metastatic breast cancer patients has previously been reported, but there are no consistent data to support the clinical utility of serum HER2 extracellular domain for patients with early stage breast cancer. We aimed to evaluate the correlation between serum extracellular domain levels and tissue HER2 expression, and analyzed their relationship with clinico-pathological parameters in patients with early stage disease. Methods A prospective study was conducted on 232 breast cancer patients with stage I-III prior to treatment. Preoperative serum samples were measured by enzyme-linked immunosorbent assay. Tissue HER2 status was analyzed by immunohistochemistry and fluorescence in situ hybridization assays. Results The median serum extracellular domain concentration was 6.8 ng/ml. The best diagnostic cut-off value was 7.4 ng/ml, with 62.9% sensitivity and 85.3% specificity. High serum extracellular domain levels were reported in 89 patients (38.3%), and HER2-positive expression was observed in 77 patients (33.2%). Multivariate analysis showed that elevated serum extracellular domain correlated with postmenopausal status (P 〈0.001), high histological grade (P 〈0.001), negativity of both estrogen (P=0.012) and progesterone receptors (P 〈0.001), and high levels of carcinoembryonic antigen 153 (P=-0.048). Conclusions We recommend that 7.4 ng/ml should be used as the cut-off value when evaluating serum extracellular domain levels in early stage of breast cancer. Patients with high serum extracellular domain levels have a certain clinico- pathological characteristics, may provide a basis for clinical practice. 展开更多
关键词 early breast cancer enzyme-linked immunosorbent assay fluorescence in situ hybridization assay human epidermal growth factor receptor 2 IMMUNOHISTOCHEMISTRY
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部